Article

Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021

2022-03-15

Abstract excerpt

<h4>Background</h4> By March 2022, around 34 million people in Colombia had received a complete scheme of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including, mRNA-based vaccines, viral vectored coronavirus vaccines, or the inactivated whole virus vaccine. However, as several SARS-CoV-2 variants of concern (VOC) and interest (VOI) co-circulate in the country, determining the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2819dbb3-0e8d-51a7-8d76-0e663b8b9fc4
DOI: 10.1101/2022.03.15.22272371

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021DOI 10.1101/2022.03.15.22272371Read

Severe acute respiratory syndrome coronavirus 2 breakthrough infections in healthcare workers vaccinees with BNT162b2 (Pfizer-BioNtech) in Bogotá, ColombiaSemantic proximity Read

Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individualsSemantic proximity Read

Efficacy of the CoronaVac® Vaccine in a Region of the Colombian Amazon, Was Herd Immunity Achieved?Semantic proximity Read

SARS-CoV-2 Vaccinated Breakthrough Infections With Fatal and Critical Outcomes in the Department of Antioquia, ColombiaSemantic proximity Read

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trialSemantic proximity Read

Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited seraSemantic proximity Read

Effectiveness of the Booster Dose in Protecting against COVID 19, Colombia 2022Semantic proximity Read

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)Semantic proximity Read

The Contributions of Vaccination and Natural Infection to the Production of Neutralizing Antibodies Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Prototype Strain and VariantsSemantic proximity Read

Toward an Integrated Response to Arboviral Threats in the Americas: Perspectives from the Dengue Summit of the Global Health Conference of the Americas 2025Semantic proximity Read

SARS-CoV-2 Seroprevalence, Cumulative Infections, and Immunity to Symptomatic Infection – A Multistage National Household Survey and Modeling Study, Dominican Republic, June–October 2021Semantic proximity Read

Effectiveness of ChAdOx1 nCoV-19 Corona Virus Vaccine (Covishield™) in preventing SARS-CoV2 infection, Chennai, Tamil Nadu, India, 2021Semantic proximity Read